Skip to main content
SpringerLink
Log in

Pasireotide LAR

  • Farmaci Innovativi in Endocrinologia
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Bruns C, Lewis I, Briner U et al. (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707–716

    Article  CAS  PubMed  Google Scholar 

  2. Petersenn S, Bollerslev J, Arafat AM et al. (2014) Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. J Clin Pharmacol 54(11):1308–1317

    Article  CAS  PubMed  Google Scholar 

  3. Lacroix A, Gu F, Gallardo W et al. (2018) Efficacy and safety of once-monthly pasireotide in Cushing’s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6(1):17–26

    Article  CAS  PubMed  Google Scholar 

  4. Colao A, Bronstein MD, Freda P et al. (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99(3):791–799

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gadelha MR, Bronstein MD, Brue T et al. (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875–884

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. U.O. Clinica Endocrinologica, IRCCS Ospedale Policlinico San Martino, Genova, Italia

    Claudia Campana, Diego Ferone & Federico Gatto

  2. Università degli Studi di Genova, Genova, Italia

    Claudia Campana & Diego Ferone

Authors
  1. Claudia Campana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diego Ferone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Federico Gatto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Federico Gatto.

Ethics declarations

Conflitto di interesse

Claudia Campana dichiara di non aver conflitti di interesse. Diego Ferone ha ricevuto compensi per l’attività di relatore e la partecipazione ad Advisory Boards da parte di Novartis, Ipsen e Pfizer. Federico Gatto ha ricevuto compensi per l’attività di relatore e la partecipazione ad Advisory Boards per AMCo, IONIS Pharmaceutical e Novartis.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Campana, C., Ferone, D. & Gatto, F. Pasireotide LAR. L'Endocrinologo 19, 339–341 (2018). https://doi.org/10.1007/s40619-018-00509-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-018-00509-6

Search

Navigation